---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-111832"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-04-24T23:59:59+00:00"
generated_at: "2026-06-16T19:10:27.164866+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected

## Summary
- 100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.
- Gamma-delta T cells expanded 82.9x at Dose Level 2 vs. standard haploidentical HSCT at 60 days.
- Dose Level 2 selected as recommended Phase 2 dose based on safety, tolerability, and expansion data.
- No dose-limiting toxicities observed; all GvHD low-grade and steroid-responsive.
- Conference call today at 10 a.m. ET; updated data expected at future medical meeting.

## SEC filing metadata
- accession: 0001193125-23-111832
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/0001193125-23-111832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/d421859d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-111832
- JSON: https://secwatch.observer/filing/0001193125-23-111832.json
- Plain text: https://secwatch.observer/filing/0001193125-23-111832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.